Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis

Leishmania major (L. major) causes cutaneous leishmaniasis in the Old World. The infection mostly induces a localized lesion restricted to the sand fly bite. The costs and the side effects of current treatments render imperative the development of new therapies that are affordable and easy to admini...

Full description

Saved in:
Bibliographic Details
Published inMicroorganisms (Basel) Vol. 8; no. 11; p. 1803
Main Authors Martínez-Salazar, Berenice, Carregaro Pereira, Vanessa, Hauyon-La-Torre, Yazmin, Khamesipour, Ali, Tacchini-Cottier, Fabienne
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 17.11.2020
MDPI
Subjects
anti-leishmanial drug
Bone marrow
Cell division
Cutaneous leishmaniasis
Dermis
Heat
Immune response
Infections
Insect bites
L. major
Leishmania
Lesions
MF-29
Neutrophils
Parasites
Parasitic diseases
Promastigotes
Side effects
Topical application
topical treatment
Tropical diseases
Tubulin
Vector-borne diseases
Online AccessGet full text

Cover

More Information
Summary:Leishmania major (L. major) causes cutaneous leishmaniasis in the Old World. The infection mostly induces a localized lesion restricted to the sand fly bite. The costs and the side effects of current treatments render imperative the development of new therapies that are affordable and easy to administrate. Topical treatment would be the ideal option for the treatment of cutaneous leishmaniasis. MF29 is a 3-haloacetamidobenzoate that was shown in vitro to inhibit tubulin assembly in Leishmania. Here, we tested a topical cream formulated with MF29. BALB/c mice were infected in the ear dermis with L. major metacyclic promastigotes and once the lesion appeared, mice were treated with different concentrations of MF29 and compared to the control group treated with the cream used as the vehicle. We observed that topical application of MF29 reduced the progression of the infection while control groups developed an unhealing lesion that became necrotic. The treatment decreased the type 2 immune response. Comparison with SinaAmphoLeish, another topical treatment, revealed that MF29 treatment once a day was sufficient to control lesion development, while application SinaAmphoLeish needed applications twice daily. Collectively, our data suggest that MF-29 topical application could be a promising topical treatment for cutaneous leishmaniasis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2076-2607
2076-2607
DOI:10.3390/microorganisms8111803